GRAS self-determination inventory database (GSID)
While not a regulatory requirement, a new database of self-affirmed GRAS (Generally Recognized as Safe) determinations has been launched to tackle concerns about a lack of transparency in the process.
Its creator – AIBMR Life Sciences – said the response to the new GRAS Self-Determination Inventory Database (GSID) has been “overwhelmingly positive and supportive”.
AIBMR’s senior research director Dr Alex Schauss said: "Each time additions are made, and the database updated, the date for that update will appear on the first page at the top. We will also take a substance off the list if it has successfully received a ‘no comment’ letter from the Food and Drug Administration (FDA) and added to the agency's voluntary notification GRAS database.”